Baralgetas
Baralgetas: instructions for use and reviews
- 1. Release form and composition
- 2. Pharmacological properties
- 3. Indications for use
- 4. Contraindications
- 5. Method of application and dosage
- 6. Side effects
- 7. Overdose
- 8. Special instructions
- 9. Application during pregnancy and lactation
- 10. Use in childhood
- 11. In case of impaired renal function
- 12. For violations of liver function
- 13. Analogs
- 14. Terms and conditions of storage
- 15. Reviews
- 16. Price in pharmacies
Latin name: Baralgetas
ATX code: A03DA02
Active ingredient: metamizole sodium + pitofenone + fenpiverinium bromide (metamizole sodium + pitofenone + fenpiverinium bromide)
Manufacturer: JUGOREMEDIJA (Serbia)
Description and photo update: 2019-13-08
Baralgetas is a non-narcotic combined remedy that relieves pain and spasms.
Release form and composition
Dosage forms of the drug:
- Tablets (10 pcs. In blisters, 1 or 10 blisters in a cardboard box);
- Solution for intramuscular and intravenous administration (in dark glass ampoules, in a carton pack of 5 ampoules).
Content of active substances in 1 tablet / ampoule of Baralgetas:
- Metamizole sodium - 500 mg;
- Pitofenone hydrochloride - 5 mg;
- Fenpiverinium bromide - 0.1 mg.
Metamizole sodium has antipyretic and analgesic effects, fenpiverinium bromide and pitofenone hydrochloride relax the smooth muscles of the internal organs. The action of pitofenone hydrochloride is similar to that of papaverine.
Pharmacological properties
Pharmacodynamics
Baralgetas is a combined analgesic and antispasmodic drug, the components of which mutually reinforce each other's pharmacological action.
Metamizole sodium, which is a pyrazolone derivative, provides antipyretic, analgesic and weak anti-inflammatory effect due to inhibition of prostaglandin synthesis.
Fenpiverinium bromide has an m-anticholinergic effect, and additionally has a myotropic effect on smooth muscles.
Pitofenone hydrochloride provides a direct myotropic effect on smooth muscles, causing it to relax (papaverine-like effect).
Pharmacokinetics
Metamizole sodium
Metamizole sodium after oral administration is rapidly absorbed from the gastrointestinal tract. In the intestinal wall, the substance is hydrolyzed to form an active metabolite. In the blood, unchanged metamizole sodium is not detected (in an insignificant concentration it is in the blood plasma only after intravenous administration, and it quickly becomes unavailable for determination). As a result of intramuscular injection, a significant proportion of the drug's components are rapidly absorbed from the injection site. Approximately 50-60% of the substance binds to plasma proteins. When taken in therapeutic doses, it is excreted into breast milk.
In the liver, there is an intensive biotransformation of sodium metamizole. Major metabolites: 4-methylaminoantipyrine, 4-aminoantipyrine, 4-acetylaminoantipyrine, 4-formylaminoantipyrine. Approximately 20 additional metabolites have been identified, including glucuronic acid derivatives. Four major metabolites are released into the cerebrospinal fluid. Metamizole sodium is mainly excreted by the kidneys.
Fenpiverinium bromide
Fenpiverinium bromide after oral administration is rapidly absorbed from the gastrointestinal tract. The maximum concentration in the blood plasma is reached after 1 hour. It does not penetrate the blood-brain barrier. From 32.4 to 40.4% is excreted in the urine unchanged, and from 2.3 to 5.3% with bile.
Pitofenone
Pitofenone is rapidly absorbed from the gastrointestinal tract after oral administration. The maximum concentration in the blood plasma is reached after 0.5-1 hours. It is quickly distributed in tissues and organs, does not penetrate the blood-brain barrier. By oxidative reactions it is metabolized in the liver. It is excreted in the urine. The half-life is 1.8 hours.
Indications for use
According to the instructions, Baralgetas is recommended for moderate to mild pain caused by muscle spasms of internal organs (spasms of the bladder and ureters, renal, intestinal and biliary colic).
The appointment of Baralgetas is also effective for dyskinesia of the bile ducts, chronic colitis, algodismenorrhea, postcholecystectomy syndrome, diseases of the pelvic organs.
The pain reliever can be used in the short-term therapy of myalgia, sciatica, arthralgia, neuralgia and as a pain reliever after surgery and diagnostic procedures.
Contraindications
- Suppression of the hematopoietic function of the bone marrow;
- Severe renal and hepatic impairment;
- Tachyarrhythmia, angina pectoris, decompensated heart failure;
- Closed-angle glaucoma;
- Hyperplasia of the prostate;
- Bowel obstruction;
- Collapse;
- Hypersensitivity;
- Pregnancy, lactation.
Do not administer the drug intravenously to children under 3 months or weighing less than 5 kg.
Baralgetas tablets are contraindicated in children under 5 years of age.
With caution, the drug should be taken with hepatic and renal failure, bronchial asthma, a tendency to low blood pressure, hypersensitivity to anti-inflammatory nonsteroidal drugs.
Instructions for use of Baralgetas: method and dosage
Pills
Recommended dosage for different age groups:
- Children 5-7 years: single dose - 1 / 2 tablet, the maximum daily - 2 tablets;
- Children 8-11 years: single - 1 / 2 tablet, the maximum daily - 4 tablets;
- Children 12-14 years old: single - 1 tablet, maximum daily dose - 6 tablets;
- Adolescents over 15 years old and adults: a single dose of 1-2 tablets, the frequency of administration is 2-3 times a day.
Solution for intramuscular and intravenous administration
The drug is administered intravenously to adolescents over 15 years of age and adults with severe and acute colic - in the amount of 2 ml. Baralgetas should be injected slowly, 1 ml for 1 minute. If necessary, the solution can be injected again - after 6-8 hours. Intramuscularly Baralgetas is administered 2-3 times a day, 2-5 ml. The permissible daily dose is 10 ml, the duration of treatment is 5 days.
For children, the drug as an anesthetic can be administered intramuscularly and intravenously in accordance with age:
- 3-11 months: in a volume of 0.1-0.2 ml and only intramuscularly;
- 1-2 years: 0.2-0.3 ml intramuscularly or 0.1-0.2 ml intravenously;
- 3-4 years: 0.3-0.4 ml intramuscularly or 0.2-0.3 ml intravenously;
- 5-7 years: 0.4-0.5 ml intramuscularly or 0.3-0.4 ml intravenously;
- 8-12 years: 0.6-0.7 ml intramuscularly or 0.5-0.6 ml intravenously;
- 12-15 years: 0.8-1.0 ml intramuscularly or intravenously.
Before injection, the ampoule with the drug should be held in your hand to warm the solution to room temperature.
Side effects
- Allergic reactions: urticaria, angioedema, erythema, epidermal toxic necrolysis, bronchospasm, anaphylactic shock;
- Urinary system: impaired renal function, anuria, proteinuria, oliguria, nephritis, discoloration of urine;
- Hematopoietic organs: agranulocytosis, leukopenia, thrombocytopenia;
- Cardiovascular system: lowering blood pressure;
- Anticholinergic effects: tachycardia, paresis of accommodation, dryness of the oral mucosa, difficulty urinating, decreased sweating;
- Local reactions: with intramuscular injection, infiltrates at the injection site are possible.
In case of an overdose, vomiting, drowsiness, nausea, epigastric pain, decreased pressure, impaired renal and hepatic function, convulsions appear. In these cases, the patient's stomach is washed, and activated charcoal is given to drink.
Overdose
Symptoms: gastralgia, hypothermia, nausea, vomiting, tachycardia, decreased blood pressure, shortness of breath, drowsiness, tinnitus, impaired consciousness, delirium, hemorrhagic syndrome, acute agranulocytosis, oliguria, acute hepatic and / or renal failure, respiratory muscle paralysis, convulsions …
Treatment: gastric lavage, the appointment of water-salt solutions, activated carbon, forced diuresis, hemodialysis. In case of convulsive syndrome, intravenous administration of fast-acting barbiturates and diazepam is recommended.
special instructions
When using Baralgetas, you should not consume substances containing ethanol.
In the case of a long (more than one week) intake of the medication, it is necessary to monitor the functional state of the liver and the picture of peripheral blood.
You can not take Baralgetas to relieve acute abdominal pain until its cause is identified.
You should immediately stop taking the medication if you suspect agranulocytosis, as well as if thrombocytopenia is detected.
Breastfeeding women should stop breastfeeding during treatment.
The use of Baralgetas by children under 5 years of age and patients receiving cytotoxic drugs should be carried out under the supervision of a physician.
For intramuscular injection, use a long, thin needle.
The probable red color of urine (excretion of the metabolite) is of no clinical significance.
Occupation with potentially hazardous types of work, control of complex mechanisms, vehicles must be done with caution, since the speed of mental and physical reactions can be reduced.
Application during pregnancy and lactation
It is forbidden to use Baralgetas during pregnancy (especially during the first trimester and the last 6 weeks).
If it is necessary to use Baralgetas during lactation, it is necessary to stop breastfeeding.
Pediatric use
It is forbidden to use the drug for intravenous administration to patients under the age of 3 months, as well as in the treatment of children weighing up to 5 kg. The use of Baralgetas tablets is contraindicated under the age of 5 years.
With impaired renal function
In case of severe renal failure, Baralgetas should not be used. In renal failure, the drug must be used with caution.
For violations of liver function
In case of severe hepatic impairment, Baralgetas should not be used. In hepatic insufficiency, the drug should be used with caution.
Analogs
Baralgetas analogs for active active ingredients: Bral, Bralangin, Maksigan, Plenalgin, Revalgin, Renalgan, Spazgan, Spazmalgon, Spazmalin, Spazmoblok, Spazmogard, Trinalgin, Geomag.
Analogs similar in the mechanism of action: Akofil, Analgin, Andipal, Antipyrin, Baralgin M, Benalgin, Quintalgin, Pentabufen, Pentalgin, Santoperalgin, Sedal-M, Sedalgin-Neo, Tempalgin, Tempanginol, Tetralgin, Quatrox.
Terms and conditions of storage
Store in a dry place protected from light, at room temperature not exceeding 25 ° C.
The shelf life is 5 years.
Reviews about Baralgetas
Reviews about Baralgetas are quite diverse. Users who follow the doctor's recommendations, take the drug in the recommended doses and monitor side effects, respond positively to Baralgetas. People who, without advice from a doctor, use this remedy for the emergency relief of pains of various origins and do not delve into the study of contraindications and side effects, give the drug a negative assessment.
Price for Baralgetas in pharmacies
The approximate price for Baralgetas is: 100 tablets - 150 rubles, 5 ampoules - 250 rubles.
Anna Kozlova Medical journalist About the author
Education: Rostov State Medical University, specialty "General Medicine".
Information about the drug is generalized, provided for informational purposes only and does not replace the official instructions. Self-medication is hazardous to health!
